Evidence map›Paper›PMID 37731630›Full record

ArticleFrontiers in oncology2023

Delta radiomic patterns on serial bi-parametric MRI are associated with pathologic upgrading in prostate cancer patients on active surveillance: preliminary findings.

Abhishek Midya, Amogh Hiremath, Jacob Huber, Vidya Sankar Viswanathan, Danly Omil-Lima, Amr Mahran, Leonardo K Bittencourt, Sree Harsha Tirumani, Lee Ponsky, Rakesh Shiradkar and 1 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abhishek MidyaDepartment of Biomedical Engineering, Emory University, Atlanta, GA, United States.
Amogh HiremathPicture Health, Cleveland, OH, United States.
Jacob HuberDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States.
Vidya Sankar ViswanathanDepartment of Biomedical Engineering, Emory University, Atlanta, GA, United States.
Danly Omil-LimaFox Chase Cancer Center, Philadelphia, PA, United States.
Amr MahranDepartment of Urology, Assiut University, Asyut, Egypt.
Leonardo K BittencourtDepartment of Radiology, University Hospitals, Cleveland Medical Center, Cleveland, OH, United States.
Sree Harsha TirumaniDepartment of Radiology, University Hospitals, Cleveland Medical Center, Cleveland, OH, United States.
Lee PonskyDepartment of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, United States.
Rakesh ShiradkarDepartment of Biomedical Engineering, Emory University, Atlanta, GA, United States.
Anant MadabhushiDepartment of Biomedical Engineering, Emory University, Atlanta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to quantify radiomic changes in prostate cancer (PCa) progression on serial MRI among patients on active surveillance (AS) and evaluate their association with pathologic progression on biopsy. Methods: This retrospective study comprised Results: An AUC of 0.64 ± 0.09 was obtained for Conclusion: Our preliminary findings suggest that delta radiomics were more strongly associated with upgrade events compared to PIRADS and other clinical variables. Delta radiomics on serial MRI in combination with changes in clinical variables (PSA and tumor volume) between baseline and follow-up showed the strongest association with biopsy upgrade in PCa patients on AS. Further independent multi-site validation of these preliminary findings is warranted.

Indexed as

active surveillancemagnetic resonance imaginingpathologic upgradeprostate cancerradiomics

Identifiers

PMID37731630
PMCPMC10508842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.